Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASES
Han S. H., De Klerk J. M. H., Zonnenberg B. A. *, Tan S., Van Rijk P. P.
From the Department of Nuclear Medicine
*Oncology Section, Department of Internal Medicine, University Medical Center Utrecht, The Netherlands
Pain palliation with bone-seeking radiopharmaceuticals is an effective treatment modality in patients with advanced metastatic bone cancer. Several studies have shown encouraging clinical results of palliative therapy using 186Re-HEDP, with an overall reported response rate of ±71% for painful osseous metastasized prostate and breast cancer patients. 186Re-HEDP is a very potential isotope with numerous advantageous characteristics for this purpose. Myelosuppressive toxicity is limited and reversible, which makes repetitive treatment safe. However, individual studies are difficult to compare, and are hampered by the numerous and different methods used to assess clinical respons. Standardized clinical response assessment using the objective multi-dimensional pain evaluation model should therefore be implemented.